Arcus Biosciences (RCUS) EBT (2017 - 2025)
Historic EBT for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to -$135.0 million.
- Arcus Biosciences' EBT fell 4673.91% to -$135.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$340.0 million, marking a year-over-year decrease of 2639.41%. This contributed to the annual value of -$282.0 million for FY2024, which is 631.23% up from last year.
- As of Q3 2025, Arcus Biosciences' EBT stood at -$135.0 million, which was down 4673.91% from -$112.0 million recorded in Q1 2025.
- Arcus Biosciences' EBT's 5-year high stood at $281.5 million during Q4 2021, with a 5-year trough of -$135.0 million in Q3 2025.
- Moreover, its 5-year median value for EBT was -$75.0 million (2021), whereas its average is -$57.8 million.
- Within the past 5 years, the most significant YoY rise in Arcus Biosciences' EBT was 64147.13% (2021), while the steepest drop was 437963.78% (2021).
- Arcus Biosciences' EBT (Quarter) stood at $281.5 million in 2021, then tumbled by 123.8% to -$67.0 million in 2022, then decreased by 19.4% to -$80.0 million in 2023, then fell by 16.25% to -$93.0 million in 2024, then plummeted by 45.16% to -$135.0 million in 2025.
- Its EBT was -$135.0 million in Q3 2025, compared to -$112.0 million in Q1 2025 and -$93.0 million in Q4 2024.